{
  "id": "adv_mhgap#risk_safety_5cf58644",
  "content": "recommendation covers the short-term use of LMICs, so advocacy is needed for better pre-hospital\nsodium valproate, the teratogenic effects may vary. management of seizures.\n77\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\nEPI2. In children with established status epilepticus, i.e. seizures\npersisting after the first-line agent (benzodiazepine-resistant\nstatus epilepticus), which antiseizure medicines are associated\nwith better clinical outcomes (stopping seizures and with less\nadverse effects)?\nRecommendation (update): In children with established status epilepticus, i.e. seizures persisting after\ntwo doses of benzodiazepines, intravenous fosphenytoin, intravenous\nphenytoin, intravenous levetiracetam, intravenous phenobarbital or\nintravenous valproic acid (sodium valproate) should be considered with\nappropriate monitoring. The choice of these medicines depends on local\nresources, including availability and facilities for monitoring.\nStrength of recommendation: Conditional\nCertainty of evidence: Moderate\nJustification Remarks\ny A new systematic review and meta-analysis was y Status epilepticus is a medical emergency which can\nconducted to study comparisons between the lead to profound systemic and neurological damage\nASMs for status epilepticus in children: Sharma et and is associated with significant short-term and\nal., 2023 (12 RCTs).13 There is moderate- to high- long-term mortality. Timely control of status",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "medium",
    "topics": [
      "study",
      "risk_safety",
      "management"
    ],
    "is_clinical": true,
    "is_advice": true
  },
  "index_text": "General â€” Risk Safety recommendation covers the short-term use of LMICs, so advocacy is needed for better pre-hospital\nsodium valproate, the teratogenic effects may vary. management of seizures.\n77\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\nEPI2. In children with established status epilepticus, i.e. seizures\npersisting after the first-line agent (benzodiazepine-resistant\nstatus epilepticus), which antiseizure medicines are associated\nwith better clinical outcomes (stopping seizures and with less\nadverse effects)?\nRecommendation (update): In children with established status epilepticus, i.e. seizures persisting after\ntwo doses of benzodiazepines, intravenous fosphenytoin, intravenous\nphenytoin, intravenous levetiracetam, intravenous phenobarbital or\nintravenous valproic acid (sodium valproate) should be considered with\nappropriate monitoring. The choice of these medicines depends on local\nresources, including availability and facilities for monitoring.\nStrength of recommendation: Conditional\nCertainty of evidence: Moderate\nJustification Remarks\ny A new systematic review and meta-analysis was y Status epilepticus is a medical emergency which can\nconducted to study comparisons between the lead to profound systemic and neurological damage\nASMs for status epilepticus in children: Sharma et and is associated with significant short-term and\nal., 2023 (12 RCTs).13 There is moderate- to high- long-term mortality. Timely control of status Recommendation covers the short-term use of lmics, so advocacy is needed for better pre-hospital\nsodium valproate, the teratogenic effects may vary. management of seizures."
}